相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma
Ymera Pignochino et al.
BMC CANCER (2015)
Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance)
Neal E. Ready et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations
M. Moschetta et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice
Dipti K. Pawaskar et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47)
Craig L. Slingluff et al.
CLINICAL CANCER RESEARCH (2013)
Everolimus vs. Temsirolimus for Advanced Renal Cell Carcinoma: Use and Use of Resources in the US Oncology Network
Nicholas J. Vogelzang et al.
CLINICAL GENITOURINARY CANCER (2013)
Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial
Michele Reni et al.
EUROPEAN JOURNAL OF CANCER (2013)
Quantification of Sunitinib and N-Desethyl Sunitinib in Human EDTA Plasma by Liquid Chromatography Coupled With Electrospray Ionization Tandem Mass Spectrometry: Validation and Application in Routine Therapeutic Drug Monitoring
Nienke A. G. Lankheet et al.
THERAPEUTIC DRUG MONITORING (2013)
Two Drug Interaction Studies of Sirolimus in Combination with Sorafenib or Sunitinib in Patients with Advanced Malignancies
Tara C. Gangadhar et al.
CLINICAL CANCER RESEARCH (2011)
Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors
Ana Batista et al.
EXPERIMENTAL HEMATOLOGY (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Phase II Trial of Bevacizumab plus Everolimus for Patients with Refractory Metastatic Colorectal Cancer
Ivy Altomare et al.
ONCOLOGIST (2011)
Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma Final Results and Analysis of Prognostic Factors
Robert J. Motzer et al.
CANCER (2010)
Efficacy of Sunitinib in Advanced Medullary Thyroid Carcinoma: Intermediate Results of Phase II THYSU
Alain Ravaud et al.
ONCOLOGIST (2010)
A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors
Brian I. Rini et al.
CLINICAL CANCER RESEARCH (2009)
mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor
Heidi A. Lane et al.
CLINICAL CANCER RESEARCH (2009)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin
KR Molhoek et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2005)
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition
SY Sun et al.
CANCER RESEARCH (2005)
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
HG Wendel et al.
NATURE (2004)
分享论文
